Detalles de la búsqueda
1.
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
Gut
; 72(2): 295-305, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-35902214
2.
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Gut
; 70(10): 1884-1893, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33903149
3.
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Gut
; 70(5): 865-875, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33753421
4.
HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease.
Gastroenterology
; 158(1): 189-199, 2020 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31600487
5.
Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease.
JAMA
; 321(8): 773-785, 2019 02 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-30806694
6.
Baseline Expression of Immune Gene Modules in Blood is Associated With Primary Response to Anti-TNF Therapy in Crohn's Disease Patients.
J Crohns Colitis
; 18(3): 431-445, 2024 Mar 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37776235
7.
Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study.
Lancet Gastroenterol Hepatol
; 9(6): 521-538, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38640937
8.
Anti-TNF Biologicals Enhance the Anti-Inflammatory Properties of IgG N-Glycome in Crohn's Disease.
Biomolecules
; 13(6)2023 06 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37371534
9.
Pretreatment Vitamin D Concentrations Do Not Predict Therapeutic Outcome to Anti-TNF Therapies in Biologic-Naïve Patients With Active Luminal Crohn's Disease.
Crohns Colitis 360
; 5(3): otad026, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37265586
10.
Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn's disease.
J Crohns Colitis
; 2023 Aug 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-37551994
11.
Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Lancet Gastroenterol Hepatol
; 8(2): 145-156, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36481043
12.
The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients.
EBioMedicine
; 88: 104430, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36634565
13.
Antibody responses to Influenza vaccination are diminished in patients with inflammatory bowel disease on infliximab or tofacitinib.
J Crohns Colitis
; 2023 Nov 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37941436
14.
Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study.
EClinicalMedicine
; 64: 102249, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37842172
15.
Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
Aliment Pharmacol Ther
; 56(5): 783-793, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35768996
16.
Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients.
J Crohns Colitis
; 16(3): 389-397, 2022 Mar 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34473254
17.
COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
Lancet Gastroenterol Hepatol
; 7(4): 342-352, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35123676
18.
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Nat Commun
; 13(1): 1379, 2022 03 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-35296643
19.
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Lancet Gastroenterol Hepatol
; 7(11): 1005-1015, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36088954
20.
Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays.
Aliment Pharmacol Ther
; 53(1): 128-137, 2021 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33226651